137 related articles for article (PubMed ID: 28002208)
1. Ovarian Cancer Follow-up: A Preliminary Comparison of 2 Approaches.
Lanceley A; Berzuini C; Burnell M; Gessler S; Morris S; Ryan A; Ledermann JA; Jacobs I
Int J Gynecol Cancer; 2017 Jan; 27(1):59-68. PubMed ID: 28002208
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of follow-up strategies for women with epithelial ovarian cancer following completion of primary treatment.
Zachou G; El-Khouly F; Dilley J
Cochrane Database Syst Rev; 2023 Aug; 8(8):CD006119. PubMed ID: 37650760
[TBL] [Abstract][Full Text] [Related]
3. Randomized study of sequential cisplatin-topotecan/carboplatin-paclitaxel versus carboplatin-paclitaxel: effects on quality of life.
Brotto L; Brundage M; Hoskins P; Vergote I; Cervantes A; Casado HA; Poveda A; Eisenhauer E; Tu D; ; ;
Support Care Cancer; 2016 Mar; 24(3):1241-9. PubMed ID: 26304156
[TBL] [Abstract][Full Text] [Related]
4. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer.
Greimel E; Bottomley A; Cull A; Waldenstrom AC; Arraras J; Chauvenet L; Holzner B; Kuljanic K; Lebrec J; D'haese S;
Eur J Cancer; 2003 Jul; 39(10):1402-8. PubMed ID: 12826043
[TBL] [Abstract][Full Text] [Related]
5. Mental distress, quality of life and social support in recurrent ovarian cancer patients during active chemotherapy.
Wen Q; Shao Z; Zhang P; Zhu T; Li D; Wang S
Eur J Obstet Gynecol Reprod Biol; 2017 Sep; 216():85-91. PubMed ID: 28738296
[TBL] [Abstract][Full Text] [Related]
6. Validation of the Mexican-Spanish Version of the EORTC QLQ-OV28 Instrument for the Assessment of Quality of Life in Women with Ovarian Cancer.
Gallardo-Rincón D; Toledo-Leyva A; Bahena-González A; Montes-Servín E; Muñoz-Montaño W; Coronel-Martínez J; Oñate-Ocaña LF
Arch Med Res; 2020 Oct; 51(7):690-699. PubMed ID: 32768148
[TBL] [Abstract][Full Text] [Related]
7. Association of financial status and the quality of life in Chinese women with recurrent ovarian cancer.
Shao Z; Zhu T; Zhang P; Wen Q; Li D; Wang S
Health Qual Life Outcomes; 2017 Jul; 15(1):144. PubMed ID: 28716032
[TBL] [Abstract][Full Text] [Related]
8. Monitoring physical and psychosocial symptom trajectories in ovarian cancer patients receiving chemotherapy.
Meraner V; Gamper EM; Grahmann A; Giesinger JM; Wiesbauer P; Sztankay M; Zeimet AG; Sperner-Unterweger B; Holzner B
BMC Cancer; 2012 Feb; 12():77. PubMed ID: 22373218
[TBL] [Abstract][Full Text] [Related]
9. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
Andre T; Amonkar M; Norquist JM; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Sevilla I; De La Fouchardiere C; Rivera F; Elez E; Diaz LA; Yoshino T; Van Cutsem E; Yang P; Farooqui M; Le DT
Lancet Oncol; 2021 May; 22(5):665-677. PubMed ID: 33812497
[TBL] [Abstract][Full Text] [Related]
10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
11. Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy.
Greimel E; Kristensen GB; van der Burg ME; Coronado P; Rustin G; del Rio AS; Reed NS; Nordal RR; Coens C; Vergote I;
Gynecol Oncol; 2013 Nov; 131(2):437-44. PubMed ID: 23994107
[TBL] [Abstract][Full Text] [Related]
12. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Garassino MC; Gadgeel S; Esteban E; Felip E; Speranza G; Domine M; Hochmair MJ; Powell S; Cheng SY; Bischoff HG; Peled N; Reck M; Hui R; Garon EB; Boyer M; Wei Z; Burke T; Pietanza MC; Rodríguez-Abreu D
Lancet Oncol; 2020 Mar; 21(3):387-397. PubMed ID: 32035514
[TBL] [Abstract][Full Text] [Related]
13. Health-related quality of life in early breast cancer.
Groenvold M
Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
[TBL] [Abstract][Full Text] [Related]
14. OVPSYCH2: A randomized controlled trial of psychological support versus standard of care following chemotherapy for ovarian cancer.
Frangou E; Bertelli G; Love S; Mackean MJ; Glasspool RM; Fotopoulou C; Cook A; Nicum S; Lord R; Ferguson M; Roux RL; Martinez M; Butcher C; Hulbert-Williams N; Howells L; Blagden SP
Gynecol Oncol; 2021 Aug; 162(2):431-439. PubMed ID: 34059348
[TBL] [Abstract][Full Text] [Related]
15. Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire core 30 scores in patients with ovarian cancer.
Musoro JZ; Coens C; Greimel E; King MT; Sprangers MAG; Nordin A; van Dorst EBL; Groenvold M; Cocks K; Velikova G; Flechtner HH; Bottomley A;
Gynecol Oncol; 2020 Nov; 159(2):515-521. PubMed ID: 32972782
[TBL] [Abstract][Full Text] [Related]
16. Determinants of quality of life in ovarian cancer survivors: a pilot study.
Teng FF; Kalloger SE; Brotto L; McAlpine JN
J Obstet Gynaecol Can; 2014 Aug; 36(8):708-715. PubMed ID: 25222166
[TBL] [Abstract][Full Text] [Related]
17. Health-related quality of life after interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with stage III ovarian cancer.
Koole SN; Kieffer JM; K Sikorska ; Schagen van Leeuwen JH; Schreuder HWR; Hermans RH; de Hingh IH; van der Velden J; Arts HJ; van Ham MAPC; Aalbers AG; Verwaal VJ; Van de Vijver KK; Sonke GS; van Driel WJ; Aaronson NK
Eur J Surg Oncol; 2021 Jan; 47(1):101-107. PubMed ID: 31128948
[TBL] [Abstract][Full Text] [Related]
18. Quality of life outcomes from the randomized trial of hyperthermic intraperitoneal chemotherapy following cytoreductive surgery for primary ovarian cancer (KOV-HIPEC-01).
Kim JH; Lee DE; Lee Y; Ha HI; Chang YJ; Chang SJ; Park SY; Lim MC
J Gynecol Oncol; 2022 Jul; 33(4):e54. PubMed ID: 35712968
[TBL] [Abstract][Full Text] [Related]
19. Quality of life in patients with advanced ovarian cancer after primary debulking surgery versus neoadjuvant chemotherapy: Results from the randomised SCORPION trial (NCT01461850).
Marchetti C; Giannarelli D; Vizzielli G; Ferrandina G; Tortorella L; Fanfani F; Costantini B; Pasciuto T; Scambia G; Fagotti A
BJOG; 2023 Dec; 130(13):1579-1588. PubMed ID: 37334772
[TBL] [Abstract][Full Text] [Related]
20. A study of symptoms described by ovarian cancer survivors.
Stavraka C; Ford A; Ghaem-Maghami S; Crook T; Agarwal R; Gabra H; Blagden S
Gynecol Oncol; 2012 Apr; 125(1):59-64. PubMed ID: 22155797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
